| Certara, Inc. (CERT) Q1 2025 Earnings Call Transcript |
Certara, Inc. (NASDAQ:CERT ) Q1 2025 Results Conference Call May 5, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Joe Vruwink - Baird Scott Schoenhaus - KeyBanc Capital Markets David Windley - Jefferies Dan Leonard - UBS Jeff Garro - Stephens Christine Rains - William Blair Constantine Davides - Citizens Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-05-05 23:22:02 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates |
Certara, Inc. (CERT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.10 per share a year ago. |
zacks.com |
2025-05-05 22:51:15 |
Czytaj oryginał (ang.) |
| Certara Reports First Quarter 2025 Financial Results |
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. |
globenewswire.com |
2025-05-05 20:15:00 |
Czytaj oryginał (ang.) |
| Certara to Participate in Upcoming Investor Conferences |
RADNOR, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: |
globenewswire.com |
2025-04-29 20:15:00 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Earnings Expected to Grow: Should You Buy? |
Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-28 15:05:52 |
Czytaj oryginał (ang.) |
| 3 Momentum Stocks That Could Soar Post-Market Volatility |
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground. |
marketbeat.com |
2025-04-21 12:02:54 |
Czytaj oryginał (ang.) |
| Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report |
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter. |
benzinga.com |
2025-04-14 18:08:07 |
Czytaj oryginał (ang.) |
| Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing |
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. |
globenewswire.com |
2025-04-14 12:15:00 |
Czytaj oryginał (ang.) |
| Buy Certara After The FDA Announcement |
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials. |
seekingalpha.com |
2025-04-11 17:15:50 |
Czytaj oryginał (ang.) |
| Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? |
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-04-11 15:05:32 |
Czytaj oryginał (ang.) |
| What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? |
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing. |
benzinga.com |
2025-04-11 14:44:28 |
Czytaj oryginał (ang.) |
| Certara price target raised by $4 at Baird, here's why |
21 May |
https://thefly.com |
2025-04-11 12:15:24 |
Czytaj oryginał (ang.) |
| Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities |
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions |
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. |
globenewswire.com |
2025-03-05 18:15:00 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript |
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-26 22:03:13 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates |
Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago. |
zacks.com |
2025-02-26 21:45:25 |
Czytaj oryginał (ang.) |
| Certara Reports Fourth Quarter 2024 Financial Results |
RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. |
globenewswire.com |
2025-02-26 18:15:00 |
Czytaj oryginał (ang.) |
| Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences |
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. |
globenewswire.com |
2025-01-29 18:15:00 |
Czytaj oryginał (ang.) |
| Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results |
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million |
globenewswire.com |
2025-01-15 09:55:00 |
Czytaj oryginał (ang.) |
| Final Trade: CERT, XLE, DAL, OKTA |
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders. |
youtube.com |
2025-01-10 21:14:33 |
Czytaj oryginał (ang.) |
| Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. |
globenewswire.com |
2025-01-02 18:15:00 |
Czytaj oryginał (ang.) |
| Cerrado Gold Provides an Update on its Mont Sorcier High Purity 67%+ Iron Grade Project in Quebec |
Detailed Metallurgical test work is ongoing and reaffirms production of DRI grade, 67%+ or better iron concentrate with combined Silica and Alumina below 2.5% Work Programs initiated and DRA Global appointed to deliver NI 43-101 Bankable Feasibility Study by end of Q1 2026 2022 PEA on Mont Sorcier provided an NPV8% of US$1.6 Billion for a 21-year mine life producing 5MT of Iron Concentrate per year (300,000 oz/Au equiv.) generating US$348M per annum in cash flow based upon initial capex of US$574M UKEF and TD Bank have agreed to sponsor 70% of project capital required subject to customary conditions of Export Credit Agency funding (All numbers reported in US dollars) TORONTO, ON / ACCESSWIRE / December 4, 2024 / (TSXV:CERT)(OTCQX:CRDOF) ("Cerrado" or the "Company") is pleased to provide an update on its ongoing work programs to complete a NI 43-101 Bankable Feasibility Study("BFS") by end of Q1 2026 on its High Purity, DRI Grade, +67% iron Mont Sorcier magnetite iron ore project located near Chibougamau, Quebec. |
accesswire.com |
2024-12-04 08:00:00 |
Czytaj oryginał (ang.) |
| Certara Showcases 2024 Research Wins With Over 100 Papers Published |
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list |
globenewswire.com |
2024-12-02 18:15:00 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript |
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript |
seekingalpha.com |
2024-11-06 23:09:17 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q3 Earnings Surpass Estimates |
Certara, Inc. (CERT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.11 per share a year ago. |
zacks.com |
2024-11-06 22:05:43 |
Czytaj oryginał (ang.) |
| Certara Reports Third Quarter 2024 Financial Results |
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. |
globenewswire.com |
2024-11-06 18:15:00 |
Czytaj oryginał (ang.) |
| Certara to Participate in the Stephens Annual Investment Conference |
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference. |
globenewswire.com |
2024-10-28 18:15:00 |
Czytaj oryginał (ang.) |
| Certara Appoints John Reynders as New Independent Board Member |
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024. |
globenewswire.com |
2024-10-16 20:15:00 |
Czytaj oryginał (ang.) |
| Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024 |
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. |
globenewswire.com |
2024-10-09 20:15:00 |
Czytaj oryginał (ang.) |
| Certara Completes Acquisition of Chemaxon |
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry. |
globenewswire.com |
2024-10-02 20:15:00 |
Czytaj oryginał (ang.) |
| Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon |
The final trades of the day with the Fast Money traders. |
youtube.com |
2024-09-27 22:37:45 |
Czytaj oryginał (ang.) |
| Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug |
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. |
globenewswire.com |
2024-09-18 12:00:00 |
Czytaj oryginał (ang.) |
| Certara to Participate in Upcoming Investor Conferences |
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: |
globenewswire.com |
2024-08-21 20:15:00 |
Czytaj oryginał (ang.) |
| Certara Launches Phoenix™ Version 8.5 Drug Development Software |
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. |
globenewswire.com |
2024-08-15 20:15:00 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript |
Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-08-06 23:36:02 |
Czytaj oryginał (ang.) |
| Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates |
Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago. |
zacks.com |
2024-08-06 23:27:09 |
Czytaj oryginał (ang.) |
| Certara Reports Second Quarter 2024 Financial Results |
RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024. |
globenewswire.com |
2024-08-06 20:15:00 |
Czytaj oryginał (ang.) |
| Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio |
Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software. |
globenewswire.com |
2024-07-09 20:45:00 |
Czytaj oryginał (ang.) |
| Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024 |
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. |
globenewswire.com |
2024-07-02 20:15:00 |
Czytaj oryginał (ang.) |
| Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software |
Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. |
globenewswire.com |
2024-06-17 12:00:00 |
Czytaj oryginał (ang.) |